New combo therapy aims to stop liver cancer spread in its tracks

This phase 3 trial tests whether adding targeted radiation or other local treatments to standard drug therapy can help people with liver cancer that has spread to a few spots outside the liver. All 400 participants first receive a combination of the immunotherapy sintilimab and the targeted drug lenvatinib. Those whose cancer is controlled are then randomly assigned to either continue the drugs alone or also receive local treatments to destroy remaining tumors. The main goal is to see if the combined approach improves overall survival.